A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta (R) in healthy Chinese male subjects-MedSci.cn

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta (R) in healthy Chinese male subjects

Liu, GW; Xu, ZN; Yang, W; Xue, JL; Wang, YL; Liu, ZZ; Cui, YZ; Qu, XY; Chang, TY; Yu, S; Cheng, Y; Zhou, YN; Chen, JH; Ren, Q; Wang, WH; Deng, QH; Wang, ZY; Yang, HM

Wang, ZY; Yang, HM (通讯作者)，Changchun Univ Chinese Med, Phase Clin Trial Lab 1, Affiliated Hosp, Jilin, Jilin, Peoples R China.;Wang, ZY (通讯作者)，Changchun Univ Chinese Med, Sci Res Off, Jilin, Jilin, Peoples R China.

Abstract

Background: Perjeta (R) is a recombinant, humanized monoclonal antibody that has been marketed and approved for the targeted therapy of human epiderma......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta (R) in healthy Chinese male subjects

科室

工具

服务